Featured News
FDA APPROVES OGSIVEO™ (NIROGACESTAT), AS THE FIRST MEDICAL THERAPY FOR THE TREATMENT OF ADULTS WITH PROGRESSING DESMOID TUMORS.
Filter by:
June 6, 2022
Registration Is Open For The 2022 Virtual DTRF “Together We Will” Weekend!
Read More about Registration Is Open For The 2022 Virtual DTRF “Together We Will” Weekend!
May 25, 2022
Breaking News: Springworks Therapeutics Announces Topline Results From Phase 3 DeFi Trial
January 28, 2022
DTRF Launches Radiomics Working Group To Improve Tumor Measurement
Read More about DTRF Launches Radiomics Working Group To Improve Tumor Measurement
January 24, 2022
Special Announcement: DTRF Co-Founder Marlene Portnoy Transitions To Board Of Directors
November 19, 2021
DTRF Receives Global Genes Champions Of Hope “Rare Champion In Advocacy (Foundation)” Award
October 26, 2021
Breaking News: DTRF-Funded Research Results In Two Stable Desmoid Tumor Cell Lines
Read More about Breaking News: DTRF-Funded Research Results In Two Stable Desmoid Tumor Cell Lines
October 4, 2021
Update: DTRF Submits Proposal To CDC For Specific ICD-10 Code For Desmoid Tumors
Read More about Update: DTRF Submits Proposal To CDC For Specific ICD-10 Code For Desmoid Tumors
September 30, 2021
Desmoid Tumor Awareness Month 2021 Comes To A Close
Read More about Desmoid Tumor Awareness Month 2021 Comes To A Close
September 27, 2021
DTRF Hosts Successful 2021 Virtual DTRF “Together We Will” Weekend
Read More about DTRF Hosts Successful 2021 Virtual DTRF “Together We Will” Weekend
March 3, 2021
DTRF Awarded The 2021 “Abbey S. Meyers Leadership Award”, A Nord “Rare Impact Award”
Read More about DTRF Awarded The 2021 “Abbey S. Meyers Leadership Award”, A Nord “Rare Impact Award”
March 7, 2019
Big News! DTRF’s First Grant Of 2019 Awarded To The Broad Institute Of MIT And Harvard
December 20, 2018